

C014CIP/DIV1/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1641  
Applicants : Michael J. Yellin et al.  
Serial No. : 09/343,001  
Filed : June 29, 1999  
For : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM  
(CD40-L) MONOCLONAL ANTIBODY 5C8 FOR THE  
TREATMENT OF CHRONIC INFLAMMATORY DISEASE

January 18, 2000  
New York, New York

Hon. Assistant Commissioner  
for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants make of record, the following documents, copies of which are submitted herewith:

PCT Patent Applications

PCT WO 98/30240, published July 16, 1998.  
PCT WO 98/30241, published July 16, 1998.

01/27/2000 SARAYA 00000023 061075 09343001

01 FC:126 240.00 CH

OTHER REFERENCES

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21, 1999.

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999.

Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).


For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form PTO-1449.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

Since this Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a Notice of Allowance under 37 C.F.R. § 1.311, the Commissioner is hereby authorized to charge payment of the \$240.00 fee required pursuant to 37 C.F.R. § 1.17(p) to Deposit Account No. 06-1075\*. The Commissioner is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account

No. 06-1075\*.

Respectfully submitted,

  
Margaret A. Pierri (Reg. No. 30,709)

Attorney for Applicants

  
Stanley D. Liang (Reg. No. 43,753)

Agent for Applicants


c/o FISH & NEAVE

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

I hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in the U.S. Post Office  
At 1000 1/2 Main Street  
Pittsburgh, Pa. 15222  
on January 18, 2000  
William J. Smith, B.C. 20231 on

  
Claire J. Smith

Signature of Person Signing

\* See accompanying Transmittal Letter, filed concurrently herewith in duplicate.

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C014CIP/DIV1/US	SERIAL NO. 09/343,001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Michael J. Yellin et al.	
		FILING DATE June 29, 1999	GROUP 1641

**OTHER DOCUMENTS (Including ~~Author, Title, Date, Pertinent Pages, Etc.~~)**

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.